Neopterin, a biochemical marker for the activation of cellular immune responses, is produced in large amounts specifically from macrophages upon stimulation with interferon-gamma (IFN-a). Its excretion in rivo is increased in disease states associated with T-cell activation: viral disease, tuberculosis, AIDS and acute cellular allograft rejection. In these diseases, neopterin excretion is closely related with the clinical activity of the disease. Increased concentrations of neopterin were demonstrated in a variety of autoimmune diseases. In rheumatoid arthritis and Crohn's disease, correlations of neopterin to clinical activity and to laboratory data were found. The clinical application of neopterin assay was also demonstrated in patients with systemic lupus erythematosus and ulcerative colitis. In these patients neopterin values correlated with clinical findings and response to treatment. These results suggest that neopterin measurement can be used for predicting prognosis and monitoring of patients with autoimmune disease.
Introduction
Neopterin, 6-D-erythrotrihydroxypropylpterin, is a low molecular mas compound of 253 0 that was first found to be increased in urine of patients with malignant and viral diseases in 1979 by Wachter et at (1, 2). Its molecular structure is a pyrazino-pyrimidine derivative derived from guanosinetriphosphate. As shown in Figure I , neopterin is a metabolite of dihydroneopterin-triphosphate (NH 2 P 3 ) which is an intermediate product in the biosynthetic pathway of biopterin (BH4). BH4 itself is known to serve as a cofactor in the enzymic hydroxylation of three aromatic amino acids, tyrosine, tryptophan and phenylalanine. The biological function of neopterin is still unknown but it has been observed that the cel- In vitro, the activation of human peripheral blood mononuclear cells with allogens, virally or chemical modified autologous cells and with mitogenic lectins was shown to be associated with the release of neopterin into the medium (3). These cells release neopterin also when stimulated with interferon-gamma (IFN-a) produced by activated T lymphocytes during immune response ( Figure 2 ) (4). In vivo, increased neopterin concentrations were found in diseases coupled with the activation of the cellular immune system. Neopterin increases in patients with various kinds of cancer (5) (6) (7) (8) (9) and with other diseases such as viral hepatitis (10), tuberculosis (11), malaria (12), AIDS (13), or acute graft rejection (14) . Therefore, neopterin represents a specific marker for cellular immune reactions. This review presents a survey of clinical significance of neopterin measurement particularly in auto-immune disease.
Clinical sifnificance of neopterin in autoimmune di~ease

Rheumatoid anhritis
In patients with rheumatoid arthritis, increased neopterin was' found when compared to patients with osteoarthritis or healthy persons (15) (16) (17) (18) (Table 1) . Discriminant analysis was performed for all nine variables (age, sex, disese stage, erythrocyte sedimentation rate (ESR), hemoglobin, white blood cell count, C-reactive protein (CRP), rheumatoid factor (RF) and neopterin) with ESR, CRP and neopterin as discriminating variable using the stepwise method (17) . The correct classification rate was 67.9% using only neopterin and was 64.2% using the three variables. This study revealed that the levels of urinary neopterin were the best combinations of independently significant joint predictors of clinical activity. The combination of neopterin to this combination was statistically dominant.
The simultaneous effect of medication and clinical activity of neopterin levels was observed in these patients (17) . The result showed significant association between neopterin levels and clinical activity but no significant association between neopterin levels and medication from clinical activity, but further studies are needed. Recent studies have shown that neopterin levels in synovial fluids from inflammatory joints are significantly higher than in noninflammatory joints. This increase might be caused by local production of neopterin in the inflammed joint (19, 20) .
Crohn S d~ease
In patients with Crohn's disease, the urinary neopterin levels correlated significantly with clinical activity (p=0.OOO3, positive correlation), disease duration (p=0.OOO3, negative correlation) and index of body weight (p=O.OOO4, positive correlation) (21) . The correlation of neopterin and clinical activity is not influenced by previous therapy. On the other hand, previous therapy did not show a significantly effect on neopterin excretion (p>0.05) whereas the effect of clinical activity on neopterin levels was highly significant (p = 0.(005).
The combination of hematocrit score, weekly stool frequency, number of related symptoms and rating of general well-being yielded a multiple correlation coefficient of 0.72. When neopterin was added to the variable set, the multiple correlation coefficient improved of 0.72 to 0.82. The multiple correlation coefficient of 0.82 could not be improved further by including age of patients, disease duration, sex, localization of disease, previous surgical therapy and erythrocyte sedimentation rate.
These data suggest that the urinary neopterin assay can advantageously supply clinical and laboratory parameters to assess the extent, progression and outcome in Crohn's disease.
Ulcerative colitis
A significant positive correlation between neopterin levels and clinical activity or single activity parameters e.g., frequency of stools or erythrocyte sedimentation rate in patients with ulcerative colitis has been observed (22, 23) . Neopterin levels were significantly increased in patients with active disease showing higher levels than · those with less active stage (fable 1). In addition, in two patients who achieved remission following surgical resection or medical therapy, decreased and normalized neopterin excretion was shown. This observation suggests a clinical usefulness of the urinary neopterin parameter in the assessment and long-term survey of disease activity in ulcerative colitis.
Systemic lupus erythematosus
High levels of neopterin were found in serum and urine of patients with systemic lupus erythematosus ISLE) (20, 24) . Recently, urinary neopterin concentrations and correlation with clinical activity and to ot her laboratory data have been described in these r atients (24) . All patients with active disease (n = 35) a nd with inactive disease (n = 8) revealed significantly (p<O.OOI a nd p<O.Ol) increased mean neopterin Jeyels when compared to the sex-and age paired con-69 trol group, those patients with active state being significantly higher than those in patients with inactive state (fable 1).
Serial determination of neopterin in SLE patients who had initially high levels and receiving medical therapy showed that there was a good correlation between urinary neopterin level and clinical response. The neopterin concentrations of one patient decreased to normal values within three months after the initiation of corticosteroid therapy. The second patient's condition deteriorate a , despite continued corticosteroid therapy, and the concentration of neopterin in this patients' urine increased steadily (24) . This result suggests that the urinary neopterin assay can be a useful parameter for monitoring of disease activity in SLE patients.
Discussions and Conclusions
Results obtained from patients with rheumatoid arthritis, Crohn's disease, ulcerative colitis and systemic lupus erythermatosus show a clear association between immune activation phenomena and clinical observations in patients. In the last decade, the neopterin assay h as been found to be useful in predicting prognosis and staging patients with cervical and urological cancer (8, 9) . in the diagnosis and follow (25) , in the monitoring of clinical activity of patients with inflammatory diseases (26, 27) , in predicting the clinical outcome of HIV patients (28, 29) and to early detect acute rejection after allogenic transplantation (14, 30) . The clinical significance of neopterin testing on these diseases has been summarized in reviews by several authors (31-34). More recently, Fuchs et al (35) have shown that higher neopterin concentration in urine and serum of HIV-l seropositive patients were signilicantly associated with progression of AIDS and with occurence of AIDS-associated death. They (26) also compared serum concentration of IFN-a and neopterin with serum tryptophan and kynurenine in these patients. Highest degree of correlation was found between neopterin, IFN-a and the kynurenine per tryptophan quotient. They concluded that decreased tryptophan in these patients might result from chronic immune activation which might be associated with HIV-l replication and might contribute to immunopathology of HIV-l infection. These studies suggest that neopterin might be used as a tool for assessing an activated state of cellular immune system even in the absence of typical clinical symptoms. Its importance in the predicting prognosis, the monitoring and treatment of disease is likely to be enormous.
In this survey, increased neopterin levels in patients with autoimmune disorders indicate activation of cellular immune system in patients. From the data it is evident that particularly the activated Tlymphocytes and macrophages play a major role in the pathogenesis of the diseases. The data indicate endogenous formation of interferon gamma to be associated with symptomatology of the disease. These data suggest that the urinary neopterin measurement is a useful addition to the other laboratory parameters for the diagnosis and prognosis of autoimmune disease, particulary because it is easily performed in small amount of urine and correlated well with the clinical activity of the disease.
